

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. (optional)	Document Number Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant
/L.B./		US-5,077,216	12/31/1991	Morganelli <i>et al.</i>
↑		US-5,223,241	06/29/1993	Isobe <i>et al.</i>
		US-5,747,654	05/05/1998	Pastan <i>et al.</i>
		US-6,132,992	10/17/2000	Ledbetter <i>et al.</i>
		US-2002/0155537	10/24/2002	Carter <i>et al.</i>
		US-2004/0219643	11/04/2004	Winter <i>et al.</i>
		US-2005/0214278	09/29/2005	Kakuta <i>et al.</i>
		US-2005/0267222	12/01/2005	Iwata <i>et al.</i>
		US-2006/0058511	03/16/2006	Tanikawa <i>et al.</i>
		US-2006/0159673	07/20/2006	Kojima
		US-2006/0269989	11/30/2006	Miyazaki <i>et al.</i>
		US-2007/0087381	04/19/2007	Kojima
		US-2009/0214535	08/27/2009	Igawa <i>et al.</i>
		US-2009/0297501	12/03/2009	Igawa <i>et al.</i>
		US-2010/0015133	01/21/2010	Igawa <i>et al.</i>
		US-2010/0092457	04/15/2010	Aburatani <i>et al.</i>
		US-2011/0059488	03/10/2011	Tsunoda <i>et al.</i>

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>**Please place an "X" in this column if English translation is attached.</p>			

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. (optional)	Foreign Patent Document Country Code-Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant	T**
/L.B./		AU 2002/210917	04/25/2002	Chugai Seiyaku Kabushiki Kaisha	X
↑		CA 2272245	05/28/1998	Roche Diagnostics GMBH	
		CA 2 331 641	11/11/1999	Deutsches Drebsforschungszentrum Stiftung Des Öffentlichen Rechts	
		EP 0 437 622	07/24/1991	Kyowa Hakko Kogyo Co., Ltd.	
		EP 0 562 125	09/29/1993	Toray Industries, Inc.	
		EP 0 774 511	05/21/1997	Cambridge Antibody Technology Limited	
		EP 0 811 691	12/10/1997	Kyowa Hakko Kogyo Co., Ltd.	
		EP 1 870 458	12/26/2007	Chugai Seiyaku Kabushiki Kaisha	
		EP 1 900 814	03/19/2008	Chugai Seiyaku Kabushiki Kaisha	
		DE 198 19 846 (w/English Abstract)	11/11/1999	Deutsches Krebsforsch	
		JP 3-41033 (w/English Abstract)	02/21/1991	Kyowa Hakko Kogyo KK	
		JP 8-500979 (w/English Abstract)	02/06/1996	SmithKline Beecham Corporation	
		JP 2001-523971 (w/English Abstract)	11/27/2001	Genentech, Inc.	
		JP 2002-543822 (w/English Abstract)	12/24/2002	SmithKline Beecham Corporation	
		JP 2003-515323 (w/English Abstract)	05/07/2003	Oxford Biomedica (UK) Limited	
		JP 2004-292455 (w/English Abstract)	10/21/2004	Chugai Pharmaceutical Co. Ltd.	

EXAMINER  
SIGNATURE: /Lynn Bristol/

DATE  
CONSIDERED: 08/16/2011

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*\*Please place an "X" in this column if English translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. (optional)	Foreign Patent Document Country Code-Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant	T**
/L.B./		WO 91/00739	01/24/1991	Kyowa Hakko Kogyo Co., Ltd.	
↑		WO 93/06862	04/15/1993	Toray Industries, Inc.	X
		WO 94/05690	03/17/1994	SmithKline Beecham Corporation	
		WO 96/27011	09/06/1996	Genentech, Inc.	
		WO 96/34892	11/07/1996	Bioenhancements Ltd.	
		WO 97/10354	03/20/1997	Kyowa Hakko Kogyo Co., Ltd.	X
		WO 98/22136	05/28/1998	Boehringer Mannheim GMBH	X
		WO 98/50431	11/12/1998	Genentech, Inc.	
		WO 00/44788	08/03/2000	Idec Pharmaceuticals Corporation	
		WO 00/069462	11/23/2000	SmithKline Beecham Corporation	
		WO 01/036486	05/25/2001	Oxford Biomedica (UK) Limited	
		WO 01/44282	06/21/2001	The Burnham Institute	
		WO 01/70775	09/27/2001	Curagen Corporation	
		WO 02/096457	12/05/2002	Novartis-Erfindungen Verwaltungsgesellschaft M.B. H.	
		WO 03/033538	04/24/2003	Kirin Beer Kabushiki Kaisha	X
		WO 03/086324	10/23/2003	Allos Therapeutics, Inc.	
		WO 03/087163	10/23/2003	Chugai Seiyaku Kabushiki Kaisha	X

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	/Lynn Bristol/
------------------------	----------------	---------------------	----------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*\*Please place an "X" in this column if English translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. (optional)	Foreign Patent Document Country Code-Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant	T**
/L.B./		WO 2004/019966	03/11/2004	Chugai Seiyaku Kabushiki Kaisha	X
/L.B./		WO 2004/037293	05/06/2004	Dainippon Pharmaceutical Co., Ltd.	X
/L.B./		WO 2004/111233	12/23/2004	Chugai Seiyaku Kabushiki Kaisha	X
/L.B./		WO 2005/107784	11/17/2005	Chugai Seiyaku Kabushiki Kaisha	X

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS			T**
/L.B./		ANDRIS-WIDHOPF <i>et al.</i> , "Methods for the generation of chicken monoclonal antibody fragments by phage display," <i>J. Immunol. Meth.</i> , 242:159-181 (2000).			
↑		ARNDT <i>et al.</i> , "Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment," <i>Biochemistry</i> , 37: 12918-12926 (1998).			
↑		ARNDT <i>et al.</i> , "Generation of a highly stable, internalizing anti-DC22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma," <i>Int. J. Cancer</i> , 107:822-829 (2003).			
↑		CARPENTER <i>et al.</i> , "Rational design of stable lyophilized protein formulations: some practical advice," <i>Pharmaceutical Research</i> , 14:969-975 (1997).			
↑		CARPENTER <i>et al.</i> , "Rational design of stable lyophilized protein formulations: theory and practice," <i>PharmaBiotechnol</i> , 13:109-133 (2001).			
↑		CARTER, "Bispecific human IgG by design," <i>J. Immunol. Methods</i> , 248:7-15 (2001).			
↑		CEKAITE <i>et al.</i> , "Protein Arrays: A versatile toolbox for target identification and monitoring of patient immune responses," <i>Methods Mol. Biol.</i> , 360:335-348 (2007).			
↑		CHATELLIER <i>et al.</i> , "Functional mapping of conserved residues located at the VL and VH domain interface of a Fab," <i>J. Mol. Biol.</i> , 264:1-6 (1996).			
↑		CHOWDHURY <i>et al.</i> , "Engineering scFvs for improved stability," <i>Methods Mol. Biol.</i> , 207:237-254 (2003).			
↑		CLACKSON <i>et al.</i> , "Making antibody fragments using phage display libraries," <i>Nature</i> , 352:624-628 (1991).			
↑		CLELAND <i>et al.</i> , "A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody," <i>J. Pharm. Sci.</i> , 90:310-321 (2001).			
↑		COCHLOVIUS <i>et al.</i> , "Treatment of human B cell lymphoma xenografts with a CD3 x CD 19 diabody and T cells," <i>The Journal of Immunology</i> , 165:888-895 (2000).			

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
---------------------	----------------	------------------	------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*\*Please place an "X" in this column if English translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		CREIGHTON, "Protein folding," <i>Biochem. J.</i> , 270:1-16 (1990).	
↑		DAVIES <i>et al.</i> , "Antibody VH domains as small recognition units," <i>Biotechnology (N.Y.)</i> , 13:475-479 (1995).	
		DE JONGE <i>et al.</i> , "Production and Characterization of Bispecific Single-Chain Antibody Fragments," <i>Mol. Immunol.</i> , 32:1405-1412 (1995).	
		EIJSINK <i>et al.</i> , "Rational engineering of enzyme stability," <i>J. Biotech.</i> , 113:105-120 (2004).	
		EUROPEAN PATENT OFFICE, European Search Report for Corresponding App. Ser. No. EP 06 73 0748, dated April 22, 2009, 7 pages.	
		FISH & RICHARDSON, Amendment in Reply to Action dated April 23, 2010 in Corresponding U.S. App. Ser. No. 10/530,696, filed October 22, 2010, 8 pages.	
		FISH & RICHARDSON, Amendment in Reply to Action dated April 16, 2010 in Corresponding U.S. App. Ser. No. 10/582,413, filed October 15, 2010, 11 pages.	
		FISH & RICHARDSON, Amendment and Response to Restriction Requirement mailed May 3, 2010 in Corresponding U.S. App. Ser. No. 11/910,117, filed November 2, 2010, 11 pages.	
		FISH & RICHARDSON, Reply to Restriction Requirement dated December 15, 2010 in Corresponding U.S. App. Ser. No. 12/874,872, filed January 18, 2011, 8 pages.	
		FISH & RICHARDSON, RCE and Amendment mailed October 29, 2010, in Corresponding U.S. App. Ser. No. 10/582,176, filed dated April 28, 2011.	
		EWERT <i>et al.</i> , "Biophysical properties of human antibody variable domains," <i>J. Mol. Biol.</i> , 325:531-553 (2003).	
		EWERT <i>et al.</i> , "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering," <i>Methods</i> , 34:184-199 (2004).	
		EWERT <i>et al.</i> , "Structure-based improvement of the biophysical properties of immunoglobulin V <sub>H</sub> domains with a generalizable approach," <i>Biochemistry</i> , 42:1517-1528 (2003).	
		FROKJAER <i>et al.</i> , "Protein drug stability: a formulation challenge," <i>Nature Rev Drug Discov.</i> , 4:298-306 (2005).	
		GARCIA-GONZALEZ <i>et al.</i> , "Purification of murine IgG3 and IgM monoclonal antibodies by euglobulin precipitation," <i>J. Immunol. Meth.</i> , 111:17-23 (1988).	
		GenBank: U27005.1, <i>Mus musculus</i> , isolate 7183Liv, Vh7183 Ig heavy chain variable region gene, Vh region, partial cds, 1 page (April 1996).	

EXAMINER SIGNATURE: /Lynn Bristol/	DATE 08/16/2011
CONSIDERED:	
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>**Please place an "X" in this column if English translation is attached.</p>	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		GenBank: AY081858.1, <i>Mus musculus</i> , isolate H3-9 anti-GBM immunoglobulin kappa chain variable region mRNA, partial cds, 1 page (March 2004).	
↑		GOLDSTEIN <i>et al.</i> , "Cytolytic and Cytostatic Properties of an Anti-Human FcγRI (CD64) x Epidermal Growth Factor Bispecific Fusion Protein <sup>1</sup> ," <i>J. Immunol.</i> , 158:872-879 (1997).	
		GOMBOTZ <i>et al.</i> , "The stabilization of a human IgM monoclonal antibody with poly(vinylpyrrolidone)," <i>Pharmaceutical Research</i> , 11:624-632 (1994).	
		GRUBER <i>et al.</i> , "Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in <i>Escherichia coli</i> <sup>1</sup> ," <i>J. Immunol.</i> , 152:5368-5374 (1994).	
		HOOGENBOOM <i>et al.</i> , "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," <i>Nucleic Acids Res.</i> , 19:4133-4137 (1991).	
		HOZUMI <i>et al.</i> , "Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions," <i>Proc. Natl. Acad. Sci. USA</i> , 73:3628-3632 (1976).	
		INTERNATIONAL BUREAU OF WIPO, International Preliminary Report on Patentability for Corresponding App. Ser. No. PCT/JP2006/306800, dated October 3, 2007, 6 pages.	
		JAGER <i>et al.</i> , "Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen," <i>J. Mol. Biol.</i> , 285:2005-2019 (1999).	
		JAPANESE PATENT OFFICE, International Search Report for Corresponding App. Ser. No. PCT/JP2006/306800, mailed May 16, 2006, 4 pages.	
		JUNG <i>et al.</i> , "The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V <sub>H</sub> domains," <i>J. Mol. Biol.</i> , 309:701-716 (2001).	
		KHALIFA <i>et al.</i> , "Effects on interaction kinetics of mutations at the VH-VL interface of Fabs depend on the structural context," <i>J. Mol. Recognit.</i> , 13: 127-139 (2000).	
		KIPRIYANOV <i>et al.</i> , "Generation of Recombinant Antibodies," <i>Mol. Biotechnology</i> , 12:173-201 (1999).	
		KONTERMANN, "Recombinant bispecific antibodies for cancer therapy," <i>Acta Pharmacol. Sin.</i> , 26:1-9 (2005).	
		KORN <i>et al.</i> , "Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv," <i>J. Gene Med.</i> , 6:642-651 (2004).	
		KREBBER <i>et al.</i> , "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system," <i>J. Immunol. Methods</i> , 201:35-55 (1997).	
		KURUCZ <i>et al.</i> , "Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria," <i>J. Immunol.</i> , 154:4576-4582 (1995).	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant. **Please place an "X" in this column if English translation is attached.			

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		LE GALL <i>et al.</i> , "Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody," <i>Protein Engineering Design &amp; Selection</i> , 17:357-366 (2004).	
↑		LEE <i>et al.</i> , "Reversible dimer formation and stability of the anti-tumour single chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy," <i>J. Mol. Biol.</i> , 320:107-127 (2002).	
		LITTLE <i>et al.</i> , "Of mice and men: hybridoma and recombinant antibodies," <i>Immunol. Today</i> , 21:364-370 (2000).	
		LIU <i>et al.</i> , "Functional interactions between arginine-133 and aspartate-88 in the human reduced folate carrier: evidence for a charge-pair association," <i>Biochem. J.</i> , 358:511-516 (2001).	
		MATY <i>et al.</i> , "Equilibrium unfolding of dimeric and engineered monomeric forms of Cro (F58W) repressor and the effect of added salts: evidence for the formation of folded monomer induced by sodium perchlorate," <i>Arch. Biochem. Biophys.</i> , 434:93-107 (2005).	
		MARTSEV <i>et al.</i> , "Antiferitin single-chain antibody: a functional protein with incomplete folding?" <i>FEBS Letters</i> , 441:458-462 (1998).	
		MCGUINNESS <i>et al.</i> , "Phage diabody repertoires for selection of large number of bispecific antibody fragments," <i>Nat. Biotech.</i> , 14: 1149-1154 (1996).	
		MENG <i>et al.</i> , "The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies," <i>Clin. Cancer Res.</i> , 10:1274-1281 (2004).	
		MERCHANT <i>et al.</i> , "An efficient route to human bispecific IgG," <i>Nat. Biotech.</i> , 16:677-681 (1996).	
		NIEBA <i>et al.</i> , "Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved <i>in vivo</i> folding and physical characterization of an engineered scFv fragment," <i>Protein Engineering</i> , 10:435-444 (1997).	
		NOHAILE <i>et al.</i> , "Altering dimerization specificity by changes in surface electrostatics," <i>PNAS</i> 98:3109-3114 (2001).	
		PEIPP <i>et al.</i> , "Bispecific antibodies targeting cancer cells," <i>Biochem. Soc. Trans.</i> , 30:507-511 (2002).	
		RAJAGOPAL <i>et al.</i> , "A form of anti-Tac (Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs," <i>Protein Engineering</i> , 10: 1453-1459 (1997).	
		RIDGWAY <i>et al.</i> , "'Knobs-into-holes' engineering of antibody C <sub>H</sub> 3 domains for heavy chain heterodimerization," <i>Protein Eng.</i> , 9:617-621 (1996).	
		ROUSCH <i>et al.</i> , "Somatostatin displayed on filamentous phage as a receptor-specific agonist," <i>Br. J. Pharmacol.</i> , 125:5-16 (1998).	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
---------------------	----------------	------------------	------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*\*Please place an "X" in this column if English translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		SEGAL <i>et al.</i> , "Bispecific antibodies in cancer therapy," <i>Cur. Opin. Immunol.</i> , 11:558-562 (1999).	
↑		SHALABY <i>et al.</i> , "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the <i>HER2</i> Protooncogene," <i>J. Exp. Med.</i> , 175:217-225 (1992).	
		SHARMA <i>et al.</i> , "Study of IgM aggregation in serum of patients with macroglobulinemia," <i>Clin. Chem. Lab. Med.</i> , 38:759-764 (2000).	
		SHIMBA <i>et al.</i> , "Comparative thermodynamic analyses of the Fv, Fab* and Fab fragments of anti-dansyl mouse monoclonal antibody," <i>FEBS Letters</i> , 360:247-250 (1995).	
		SHIRE <i>et al.</i> , "Challenges in the development of high protein concentration formulations," <i>J. Pharm. Sci.</i> , 93:1390-1402 (2004).	
		SKERRA, "Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in <i>Escherichia coli</i> ," <i>Gene</i> , 151:131-135 (1994).	
		TAN <i>et al.</i> , "Contributions of a highly conserved V <sub>H</sub> /V <sub>L</sub> hydrogen bonding interaction to scFv folding stability and refolding efficiency," <i>Biophys. J.</i> , 75:1473-1482 (1998).	
		TANG <i>et al.</i> , "Selection of linkers for a catalytic single-chain antibody using phage display technology", <i>J. Biol. Chem.</i> , 271: 15682-15686 (1996).	
		TURNER <i>et al.</i> , "Importance of the linker in expression of single-chain Fv antibody fragments: optimization of peptide sequence using phage display technology," <i>Journal of Immunological Methods</i> , 205:43-54 (1997).	
		UNITED STATES PATENT AND TRADEMARK OFFICE, Restriction Requirement in Corresponding U.S. App. Ser. No. 11/910,117, mailed May 3, 2010, 9 pages.	
		UNITED STATES PATENT AND TRADEMARK OFFICE, Non-Final Office Action in Corresponding U.S. App. Ser. No. 10/582,304, mailed December 9, 2010, 12 pages.	
		UNITED STATES PATENT AND TRADEMARK OFFICE, Restriction Requirement in Corresponding U.S. App. Ser. No. 12/874,872, mailed December 15, 2010, 6 pages.	
		UNITED STATES PATENT AND TRADEMARK OFFICE, Notice of Allowance in Corresponding U.S. App. Ser. No. 10/551,504, mailed December 16, 2010, 5 pages.	
		UNITED STATES PATENT AND TRADEMARK OFFICE, Non-Final Office Action in Corresponding U.S. App. Ser. No. 10/530,696, mailed January 7, 2011, 9 pages.	
		UNITED STATES PATENT AND TRADEMARK OFFICE, Non-Final Office Action in Corresponding U.S. App. Ser. No. 11/910,117, mailed January 24, 2011, 10 pages.	
		UNITED STATES PATENT AND TRADEMARK OFFICE, Notice of Allowance in Corresponding U.S. App. Ser. No. 10/551,504, mailed March 21, 2011, 7 pages.	
		VANDENBURG <i>et al.</i> , "Selection of mutations for increased protein stability," <i>Curr. Opin. Biotechnol.</i> , 13:333-337 (2002).	

EXAMINER SIGNATURE: /Lynn Bristol/	DATE 08/16/2011 CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant. **Please place an "X" in this column if English translation is attached.	



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		VARGAS-MADRAZO <i>et al.</i> , "An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues," <i>J. Mol. Recognit</i> , 16:113-120 (2003).	
↑		VIEILLE <i>et al.</i> , "Hyperthermophilic enzymes: sources, uses, and molecular mechanisms for thermostability," <i>Microbiology and Molecular Biology Reviews</i> , 65:1-43 (2001).	
		VÖLKE <i>et al.</i> , "Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies," <i>Protein Engineering</i> , 14:815-823 (2001).	
		WANG, "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <i>International Journal of Pharmaceutics</i> , 185:129-188 (1999).	
		WANG, "Lyophilization and development of solid protein pharmaceuticals," <i>International Journal of Pharmaceutics</i> , 203:1-60 (2000).	
		WANG, "Protein aggregation and its inhibition in biopharmaceutics," <i>International Journal of Pharmaceutics</i> , 289:1-30 (2005).	
		WHITLOW <i>et al.</i> , "An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability," <i>Protein Engineering</i> , 6:989-995 (1993).	
		WÖRN <i>et al.</i> , "Stability engineering of antibody single-chain Fv fragments," <i>J. Mol. Biol</i> , 305:989-1010 (2001).	
		WU <i>et al.</i> , "Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange," <i>Protein Eng.</i> , 14:1025-1033 (2001).	
		ZHU <i>et al.</i> , "Remodeling domain interfaces to enhance heterodimer formation," <i>Protein Science</i> , 6:781-788 (1997).	
		ZHU <i>et al.</i> , "An efficient route to the production of an IgG-like bispecific antibody," <i>Protein Eng.</i> , 13:361-367 (2000).	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant. **Please place an "X" in this column if English translation is attached.			